Categories: Wire Stories

Enfusion Announces Date of Fourth Quarter and Full Year 2023 Results

NEW YORK & LONDON & HONG KONG–(BUSINESS WIRE)–Enfusion, Inc. (“Enfusion”) (NYSE: ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, today announced it will release its fourth quarter and full year 2023 financial results before the U.S. financial markets open on Tuesday, March 12, 2024. Management will host a conference call and webcast that same morning at 5:30 AM (PT) / 8:30 AM (ET) to discuss the results.

To access this call, dial (888) 596-4144. The conference ID number is 9652536. A live webcast of this conference call will be available on the Investor Relations page of Enfusion’s website, http://ir.enfusion.com, and a replay will be archived on the website as well.

About Enfusion

Enfusion’s investment management software-as-a-service platform removes traditional information boundaries, uniting front-, middle- and back-office teams on one system. Through its software, analytics, and middle/back-office managed services, Enfusion creates enterprise-wide cultures of real-time, data-driven intelligence and collaboration boosting agility and powering growth. Enfusion partners with over 800 investment managers from 10 global offices spanning four continents.

Source: Enfusion, Inc.

Source Code: ENFN-IR

Contacts

Investors
Bill Wright

investors@enfusion.com

Media
media@enfusion.com

Alex

Recent Posts

CLP𝑒 Teams Up with CityUHK to Install Solar Power System Across the Campus

HONG KONG SAR - Media OutReach Newswire - 2 June 2024 - CLPe and City…

2 hours ago

OPPO Scores Unforgettable Experiences with Global Brand Ambassador Kaká at the UEFA Champions League Final 2024

LONDON, UNITED KINGDOM - Media OutReach Newswire – 1 June 2024 - The UEFA Champions…

5 hours ago

“Experience the Luxury of Japanese Tradition and Cuisine” Reservations for the New Inbound Experience Tour in Osaka’s Tondabayashi Begin on June 1, 2024!

OSAKA, Japan--(BUSINESS WIRE)--The city of Tondabayashi in Osaka is excited to announce a new inbound…

15 hours ago

Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma

− Four-year Analysis Conducted by GHSG Reported ADCETRIS + ECADD Combination Improved Progression-Free Survival, Showing…

17 hours ago

Accutar Biotechnology Presents Phase 1 Data of AC699 Monotherapy in Patients with ER+ / HER2- Breast Cancer at ASCO 2024

– Differentiated Mechanism of Action of a Chimeric Degrader as Compared to Fulvestrant and Novel…

17 hours ago

Crafting Timeless Elegance: Unique Ring Designs

Welcome to our in-depth exploration of timeless elegance in unique ring designs. Whether you are…

18 hours ago